Organoid-Guided Synthetic Micropeptide Therapeutics to Target Ovarian Cancer Stem Cells
Open Access
Abstract
Ovarian cancer remains the most lethal gynecological malignancy, largely due to high recurrence rates and the development of therapy-resistant disease. Cancer stem cells (CSCs) contribute to treatment failure by promoting chemoresistance through signaling pathways such as Wnt/β-catenin, Hedgehog, and Notch, as well as through dynamic interactions with the tumor microenvironment (TME). Ovarian CSC (OCSC)-associated biomarkers, including CD44, CD24, CD133, and ALDH, have expanded opportunities for specific tumor characterization and biomarker identification. Effective targeting of OCSCs requires experimental models that preserve cellular plasticity and hierarchical organization. Development of synthetic matrices and chemically defined media has improved the reproducibility and scalability of three-dimensional (3D) organoid cultures for preclinical drug testing. CSC-derived organoids, established by enriching cells positive for CSC markers directly from patient tumor material, provide a 3D platform for studying OCSC-associated phenotypes and therapeutic responses. This review examines current understanding of ovarian CSC biology and the development of OCSC-derived 3D organoid models that can recapitulate cellular architecture and patient-specific drug responses. These 3D organoid models provide a guided platform for evaluating emerging therapeutics, such as micropeptides encoded by short open reading frames or engineered from functional tumor-suppressor protein domains selected to target OCSCs. Their small size enables modulation of intracellular signaling and highly specific protein–protein interactions. We further review micropeptide stabilization strategies and tumor-targeted delivery systems designed to enhance bioavailability. This review highlights how integrating patient-specific OCSC-derived organoid models with engineered micropeptides may accelerate the development of personalized treatment strategies for ovarian cancer while improving the preclinical evaluation of novel therapies.Keywords
Funding Information
- Department of Biotechnology, India (BT/PR41903/MED/97/527/2021)
This publication has 151 references indexed in Scilit:
- The Activation of miR‐203a by SFRP4 Micropeptides Targets Epithelial–Mesenchymal Transition and Autophagy in Ovarian Cancer Stem CellsMolecular Carcinogenesis, 2025
- Viscoelasticity of Hyaluronic Acid Hydrogels Regulates Human Pluripotent Stem Cell‐derived Spinal Cord Organoid Patterning and VascularizationAdvanced Healthcare Materials, 2024
- Bioinspired Hyaluronic Acid‐Based Hydrogel Fuels Bi‐Directional Lung Organoid Maturation via PIEZO1 and ITGB1 Mediated MechanosensationAdvanced Materials Interfaces, 2024
- The global, regional and national epidemiology, incidence, mortality, and burden of ovarian cancerHealth Science Reports, 2022
- Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020International Journal of Cancer, 2022
- The Small Open Reading Frame‐Encoded Peptides: Advances in Methodologies and Functional StudiesChemBioChem, 2021
- Structure‐activity studies of peptidomimetics based on kinase‐inhibitory region of suppressors of cytokine signaling 1Peptide Science, 2018
- Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cellsInternational Journal of Cancer, 2011
- Injectable drug‐delivery systems based on supramolecular hydrogels formed by poly(ethylene oxide)s and α‐cyclodextrinJournal of Biomedical Materials Research Part A, 2003
- Solid‐phase synthesis of C‐terminal modified peptidesPeptide Science, 2003